Analysis of the results of a large clinical trial, EMPEROR-Preserved, shows that the SGLT2 inhibitor empagliflozin improves outcomes for heart failure patients with either mid-range (41–49%) or preserved (≥50%) ejection fraction, supporting the use of this drug for both categories of patients.
- Stefan D. Anker
- Javed Butler
- Faiez Zannad
